Funding Resources
Funding Overview
Funding Strategy
Funding Opportunities
Grant Mechanisms
Training & Career
   Development
Contracts Management
Review Committees

Funding News

Program Areas

Research
Anticonvulsant Screening
   Program
Clinical Research
Counterterrorism
Epilepsy Research Web
Neural Interfaces Program
NIH Roadmap Research
Parkinson's Web
Resources for Scientists
Stem Cell Research
Translational Research
Traumatic Brain Injury
   (TBI) Research
Technology Transfer
   Office

Contact Us
My Privacy

NINDS is part of the
National Institutes of
Health

Download Adobe Reader

  Print-friendly version

   Email this page

Researchers at the National Institute of Neurological Disorders and Stroke (NINDS) are seeking patients with HTLV-1-associated myelopathy or tropical spastic paraparesis (HAM/TSP) for an experimental treatment trial. The study will test an experimental drug's ability to ameliorate the immune dysregulation induced by HTLV-1. Testing of this drug will be carried out in compliance with FDA guidelines.

Eligible patients must be at least 16 years of age, meet diagnostic criteria for HAM/TSP, and be negative for HIV, HCV, and hepatitis B surface antigen. The studies will be conducted at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD. All study-related expenses will be paid by the NIH.

For more information, physicians should send a referral letter and a copy of the patient's recent medical records to Joan Eaton, RN, CRNP, Neuroimmunology Branch, NINDS, NIH, Building 10, Room 5B16, 10 Center Drive MSC 1430, Bethesda, MD 20892-1430; telephone: (301) 496-0064; fax: (301) 402-0373; email: eatonj@ninds.nih.gov.

---

This content has been adapted from the original NINDS Notes publication. For the most up-to-date funding information, please visit the Funding Opportunities section of the NINDS web site.  For the most recent information on NINDS studies, please visit the NINDS Patient Recruitment web site.